60

DaShenLin Pharmaceutical Group Co LtdSHG 603233 Stock Report

Last reporting period 30 Sep, 2023

Updated 21 Oct, 2024

Last price

Market cap $B

2.175

Small

Exchange

XSHG - Shanghai Stock Exchange

603233.SS Stock Analysis

60

Neutral

Based on Eyestock quantitative analysis, 603233.SS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

57/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

170.1 %

Greatly undervalued

Market cap $B

2.175

Dividend yield

1.98 %

Shares outstanding

946.28 B

DaShenLin Pharmaceutical Group Co., Ltd. engages in the retail and wholesale of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong and currently employs 38,353 full-time employees. The company went IPO on 2017-07-31. The firm's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The firm mainly conducts its business within domestic market.

View Section: Eyestock Rating